These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8693619)

  • 1. [The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease].
    Ulrik CS
    Ugeskr Laeger; 1996 Jun; 158(25):3604-7. PubMed ID: 8693619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
    Ulrik CS
    Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases].
    Beeh KM; Wiewrodt R; Salem AE; Buhl R
    Pneumologie; 2000 Jun; 54(6):225-31. PubMed ID: 10934892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
    Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K
    Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
    Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
    Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of salmeterol in stable COPD.
    Kaushik ML; Kashyap S; Bansal SK; Sharma A
    Indian J Chest Dis Allied Sci; 1999; 41(4):207-12. PubMed ID: 10661008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
    Taccola M; Bancalari L; Ghignoni G; Paggiaro PL
    Monaldi Arch Chest Dis; 1999 Aug; 54(4):302-6. PubMed ID: 10546469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
    Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
    Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B; Markham A
    Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
    Cazzola M; Vinciguerra A; Di Perna F; Matera MG
    Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
    Rennard SI; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Salmeterol and prolonged treatment of asthma: international clinical data].
    Bons J; Pappo M
    Rev Mal Respir; 1992; 9 Suppl 1():R15-8. PubMed ID: 1350364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of and tolerance to salmeterol compared to salbutamol in patients with bronchial asthma].
    De Oliveira MA; Jardim JR; Faresin SM; Lucas SR; Nery LE
    Rev Assoc Med Bras (1992); 1998; 44(3):169-75. PubMed ID: 9755543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life changes in COPD patients treated with salmeterol.
    Jones PW; Bosh TK
    Am J Respir Crit Care Med; 1997 Apr; 155(4):1283-9. PubMed ID: 9105068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
    Lundback B; Rawlinson DW; Palmer JB
    Thorax; 1993 Feb; 48(2):148-53. PubMed ID: 8493629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction].
    Vollmer M; Schmidt EW; Ulmer WT
    Pneumologie; 1995 Oct; 49(10):528-34. PubMed ID: 8584522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
    van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
    Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.